Elevated triglycerides and low high-density lipoprotein cholesterol level as marker of very high risk in type 2 diabetes

Current Opinion in Endocrinology, Diabetes, and Obesity
Michel P Hermans, Paul Valensi

Abstract

The aim of this review is to describe in diabetic patients the determinants underlying atherogenic dyslipidemia, a complex dyslipidemia defined as the coexistence of fasting hypertriglyceridemia and low high-density lipoprotein cholesterol level. Atherogenic dyslipidemia is often comorbid with hyperglycemia in patients with the common form of type 2 diabetes mellitus (T2DM), namely that associated with obesity, insulin resistance, hyperinsulinemia and the metabolic syndrome phenotype. The role of triglyceride-rich lipoproteins, both fasting and nonfasting, is increasingly considered as a direct driver of atherosclerosis in diabetic patients, even in those receiving best standards of care, including low-density lipoprotein cholesterol level adequately controlled by statins and/or ezetimibe. The residual cardiovascular risk related to atherogenic dyslipidemia in T2DM patients can be inferred from subgroup analysis of diabetic patients within landmark lipid-lowering trials, or from T2DM-only trials, such as Fenofibrate Intervention and Event Lowering in Diabetes study or Action to Control Cardiovascular Risk in Diabetes-Lipid trial. The presence of atherogenic dyslipidemia markedly increases cardiovascular risk, and there is evide...Continue Reading

References

Jan 16, 2007·Current Opinion in Lipidology·Alexander Leaf
Apr 3, 2007·Lancet·Mitsuhiro YokoyamaUNKNOWN Japan EPA lipid intervention study (JELIS) Investigators
Jun 6, 2007·Acta Clinica Belgica·M P Hermans
Mar 17, 2010·The New England Journal of Medicine·Henry N GinsbergRobert P Byington
May 21, 2010·Current Medical Research and Opinion·J C FruchartUNKNOWN International Steering Committee of R(3)i
Jul 1, 2010·The New England Journal of Medicine·UNKNOWN ACCORD Study GroupLawrence J Fine
Jun 18, 2011·Diabetic Medicine : a Journal of the British Diabetic Association·L A LeiterUNKNOWN DYSIS investigators
Jun 13, 2012·The New England Journal of Medicine·Jackie BoschSalim Yusuf
Sep 1, 2011·Therapeutic Advances in Chronic Disease·Michel P Hermans, Jean-Charles Fruchart
May 10, 2013·The New England Journal of Medicine·UNKNOWN Risk and Prevention Study Collaborative GroupRoberto Marchioli
Jan 28, 2014·Cardiovascular Diabetology·Jean-Charles FruchartUNKNOWN Residual Risk Reduction Initiative (R3i)
Mar 13, 2014·Cardiovascular Diabetology·Michel P HermansMichel F Rousseau
Aug 2, 2014·Progress in Lipid Research·Amirhossein SahebkarGerald F Watts
Feb 13, 2015·Expert Opinion on Pharmacotherapy·Shashank R Joshi
Mar 3, 2015·Diabetologia·Bruno Vergès
May 1, 2015·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Aravind SosaleBhavana Sosale
Jun 4, 2015·The New England Journal of Medicine·Christopher P CannonUNKNOWN IMPROVE-IT Investigators
Aug 28, 2016·European Heart Journal·Alberico L CatapanoUNKNOWN ESC Scientific Document Group
Jan 17, 2017·Annales d'endocrinologie·UNKNOWN French Society of Endocrinology (SFE)B Vergès
Mar 18, 2017·The New England Journal of Medicine·Marc S SabatineUNKNOWN FOURIER Steering Committee and Investigators

❮ Previous
Next ❯

Citations

Dec 5, 2019·Biomaterials Science·S BusattoP Bergese
May 12, 2020·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Tsung-Yu TsaiYu-Chen Huang
Jun 11, 2020·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Tsung-Yu TsaiYu-Chen Huang
Jul 1, 2020·Diabetes/metabolism Research and Reviews·Wenning FuZuxun Lu
Nov 27, 2019·International Journal of Molecular Sciences·Yusuke SasakiTatsuhiko Kodama
Nov 25, 2020·Diabetic Medicine : a Journal of the British Diabetic Association·Giovanni Fanni

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Biomarkers for Diabetes

This feed focuses on the latest research on biomarkers used for monitoring disease progression in diabetes.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.

Cardiovascular Disorder in Diabetes

Diabetes is associated with an increased risk of cardiovascular disorders and heart failure. Discover the latest research here.